Single-Dose Erysipelothrix and Haemophilus Parasuis Vaccine

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines for Erysipelothrix Rhusiopathiae (E. rhusiopathiae) and Haemophilus Parasuis (H. parasuis) require multiple doses, leading to increased time, expense, and risk of injury, and do not provide extended duration of immunity.

Innovation Solution

A single-dose vaccine formulation using inactivated bacterial components of E. rhusiopathiae and H. parasuis with a mineral oil-based adjuvant, such as ISA206, administered intramuscularly, which induces effective immunity and provides a duration of at least four to six months.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If multiple doses of vaccine are administered, then effective immunity is conferred, but time and expense increase and risk of injury increases

Engineering Contradiction:

Improveeffective immunityVSAvoidtime needed for multiple vaccinations

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent combines multiple vaccine antigens (E. rhusiopathiae and H. parasuis) into a single combination vaccine formulation that can be administered in one dose, thereby reducing the number of vaccination visits while maintaining effective immunity against multiple pathogens

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent modifies the vaccine formulation by incorporating specific adjuvants and optimizing antigen concentrations to enhance immunogenicity, allowing a single dose to provide prolonged immunity (at least 4-6 months) that would otherwise require multiple administrations

Inventive Principle:

Principle #35Parameter changes

2Reliability

If multiple doses of vaccine are administered, then effective immunity is conferred, but expense increases

Engineering Contradiction:

Improveeffective immunityVSAvoidexpense associated with multiple doses

Core Design Contradiction:

ReliabilityVSLoss of energy

Solution Approach 1:

The combination vaccine merges protection against E. rhusiopathiae and H. parasuis into a single product, eliminating the need for separate vaccinations and reducing overall veterinary expense while maintaining effective immunity against both pathogens

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The optimized formulation with enhanced adjuvants allows a single dose to provide prolonged immunity (at least 4-6 months), reducing the frequency of vaccinations needed and thereby lowering the cumulative expense of vaccine administration over time

Inventive Principle:

Principle #35Parameter changes

3Reliability

If multiple doses of vaccine are administered, then effective immunity is conferred, but risk of injury to animal and person increases

Engineering Contradiction:

Improveeffective immunityVSAvoidrisk of injury

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The combination vaccine consolidates multiple vaccination procedures into a single administration, eliminating repeated needle sticks and handling events that could cause injury to both animals and veterinary personnel

Inventive Principle:

Principle #5Merging (Combining)

4Loss of time

If single dose vaccine is administered, then time and expense are reduced, but duration of immunity is limited

Engineering Contradiction:

Improvetime needed for vaccinationVSAvoidduration of immunity

Core Design Contradiction:

Loss of timeVSDuration of action of moving object

Solution Approach 1:

The patent employs optimized antigen concentrations and specific adjuvant formulations to enhance the immunogenicity and persistence of the immune response, achieving prolonged immunity (at least 4-6 months) from a single dose vaccination

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The combination vaccine uses a composite formulation incorporating multiple antigens and adjuvants that work synergistically to stimulate a strong, long-lasting immune response that persists for at least 4-6 months following single administration

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS8637047B2<i>Erysipelothrix rhusiopathiae</i>-<i>haemophilus parasuis </i>vaccine and methods of using the same

Publication Date: 2014.01.28 BOEHRINGER INGELHEIM VETMEDICA INC

AI summary

The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner. The amount of the dose for intramuscular administration is preferably less than 5 ml. The amount of E. rhusiopathiae and/or H. parasuis antigen in each dose should be enough to induce an immune response in the animal receiving the vaccine or composition and will preferably confer effective immunity against and decrease the risk of developing clinical signs resulting from E. rhusiopathiae and/or H. parasuis infection for a suitable duration of immunity.